[1]JournalofMedicinalChemistry,2005,vol.48,p.4312-4331
[2]JournalofMedicinalChemistry,2005,vol.48,p.2469-2479
Title: Chemokine receptor antagonists.
Journal: Journal of medicinal chemistry 20121126
Title: CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.
Journal: The Journal of clinical investigation 20121001
Title: Elevated interleukin-8 enhances prefrontal synaptic transmission in mice with persistent inflammatory pain.
Journal: Molecular pain 20120101
Title: Changes in expression of mRNA for interleukin-8 and effects of interleukin-8 receptor inhibitor in the spinal dorsal horn in a rat model of lumbar disc herniation.
Journal: Spine 20111201
Title: Progress in structure based drug design for G protein-coupled receptors.
Journal: Journal of medicinal chemistry 20110714
Title: Inhibition of CXCR1 and CXCR2 chemokine receptors attenuates acute inflammation, preserves gray matter and diminishes autonomic dysreflexia after spinal cord injury.
Journal: Spinal cord 20110301
Title: Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats.
Journal: Biological & pharmaceutical bulletin 20110101
Title: CXC chemokine receptor-1 is expressed by hepatocytes and regulates liver recovery after hepatic ischemia/reperfusion injury.
Journal: Hepatology (Baltimore, Md.) 20110101
Title: CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.
Journal: The Journal of clinical investigation 20100201
Title: Interfering with inflammation: a new strategy to block breast cancer self-renewal and progression?
Journal: Breast cancer research : BCR 20100101
Title: A crucial role for TNF-alpha in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5.
Journal: British journal of pharmacology 20091001
Title: Development and validation of an LC-MS/MS method for determination of methanesulfonamide in human urine.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090715
Title: Novel role of CXCR2 in regulation of gamma-secretase activity.
Journal: ACS chemical biology 20081219
Title: Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice.
Journal: British journal of pharmacology 20081001
Title: The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature.
Journal: Arthritis and rheumatism 20080801
Title: Platelet activating factor receptors drive CXC chemokine production, neutrophil influx and edema formation in the lungs of mice injected with Tityus serrulatus venom.
Journal: Toxicon : official journal of the International Society on Toxinology 20070901
Title: Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord.
Journal: The Journal of pharmacology and experimental therapeutics 20070901
Title: Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
Journal: Journal of medicinal chemistry 20070823
Title: Down-regulation of CXCR2 on neutrophils in severe sepsis is mediated by inducible nitric oxide synthase-derived nitric oxide.
Journal: American journal of respiratory and critical care medicine 20070301
Title: Reparixin, a specific interleukin-8 inhibitor, has no effects on inflammation during endotoxemia.
Journal: International journal of immunopathology and pharmacology 20070101
Title: The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats.
Journal: Molecular medicine (Cambridge, Mass.) 20070101
Title: Chemokine MIP-2/CXCL2, acting on CXCR2, induces motor neuron death in primary cultures.
Journal: Neuroimmunomodulation 20070101
Title: Species differences in the pharmacokinetics and metabolism of reparixin in rat and dog.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20060501
Title: 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
Journal: Journal of medicinal chemistry 20050630
Title: Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia.
Journal: Cytokine 20050507
Title: Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion.
Journal: Kidney international 20050501
Title: Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
Journal: Journal of medicinal chemistry 20050407
Title: Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2.
Journal: Biochemical pharmacology 20050201
Title: Neutrophil recruitment in the reperfused-injured rat liver was effectively attenuated by repertaxin, a novel allosteric noncompetitive inhibitor of CXCL8 receptors: a therapeutic approach for the treatment of post-ischemic hepatic syndromes.
Journal: International journal of immunopathology and pharmacology 20050101
Title: Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.
Journal: British journal of pharmacology 20040901
Title: Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20040810
Title: Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007 Aug 23;50(17):3984-4002.
Title: Bertini R, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2non-competitive allosteric inhibitor. Br J Pharmacol. 2012 Jan;165(2):436-54.
Title: Kim HY, et al. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol Pharm Bull. 2011;34(1):120-7.
Title: Sousa LF, et al. Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice. Clinics (Sao Paulo). 2013;68(3):391-4.
Title: Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6.
Title: Krishnamurthy A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016 Apr;75(4):721-9.
Title: Crespo J, et al. Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol. 2018 Jul 15;201(2):814-820.
